GFAP and Alzheimer disease: While high-performing assays for plasma Aβ40, Aβ42, P-tau181, NfL, and GFAP effectively detect Alzheimer's disease and neurodegeneration-related pathological changes, their examination has been primarily focused on clinically based cohorts, often characterised by mild comorbidities.